---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019285"
form_type: "8-K"
ticker: "CYDY"
cik: "0001175680"
company_name: "CytoDyn Inc."
filed_at: "2023-11-21T23:59:59+00:00"
generated_at: "2026-06-07T22:29:42.063014+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CytoDyn appoints Jacob Lalezari as interim CEO, effective Nov 17, 2023

## Summary
- Dr. Lalezari appointed interim CEO; Antonio Migliarese ceases interim President but remains CFO.
- Dr. Lalezari to receive only minimum salary required by law; no cash bonus, equity, or severance.
- CytoDyn has paid ~$1.5M to Lalezari's firm Quest Clinical Research since June 2021; $0.4M outstanding.
- Board seeks permanent CEO; Lalezari expected to serve a few months to resolve clinical hold and pursue partnerships.
- Dr. Lalezari previously served as interim CMO in 2020 and has advised the company for several years.

## SEC filing metadata
- accession: 0001558370-23-019285
- form_type: 8-K
- ticker: CYDY
- cik: 0001175680
- company_name: CytoDyn Inc.
- filed_at: 2023-11-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175680/000155837023019285/0001558370-23-019285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175680/000155837023019285/cydy-20231117x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019285
- JSON: https://secwatch.observer/filing/0001558370-23-019285.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019285.txt

## Key facts
- Executive change
  Jacob P. Lalezari, M.D. was appointed as interim CEO at CytoDyn Inc..
  - Action: appointed
  - Role: interim CEO
  source text: On November 17, 2023, CytoDyn Inc., a Delaware corporation (the “Company”), entered into an employment agreement with. Jacob P. Lalezari, M.D. (the “Employment Agreement”), under which he will be employed as the Company’s interim CEO on an at-will basis, effective November 17, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837023019285/0001558370-23-019285-index.htm
- Executive change
  Antonio Migliarese changed role as interim President at CytoDyn Inc..
  - Action: ceased
  - Role: interim President
  source text: Antonio Migliarese, who was appointed as interim President on May 18, 2023, ceased being interim President on November 17, 2023, but will continue in his roles of Chief Financial Officer and Treasurer, as well as serving as the Company’s principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837023019285/0001558370-23-019285-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.